Although not efficacious for all patients, JAK1 or p19 inhibition, which modulate IFN pathways, may be effective in those anti-TNF nonresponders63–67 for whom clinical benefit outweighs infection-associated safety risks66,68. Here, JAK1 is linked to infection.